Novel Frontiers in the Production of Compounds for Biomedical Use

1. Front Matter

   Pages i-12

   PDF

2. Genomics: the New Approach to the Discovery of New Compounds

   1. The Genomics Approach: Is it Really the Solution?

      • Raul Goldschmidt, Karen Bush

      Pages 15-22

   2. The Contribution of Genomics to the Discovery of New Antibiotics

      • David J. Holmes, John P. Throup, Nicola G. Wallis, Martin K. R. Burnham, Magdalena Zalacain, Sanjoy Biswas et al.

      Pages 23-31

3. Antibiotics

   1. The Antibiotic Gallidermin-Evolution of a Production Process

      • Markus Kempf, Uwe Theobald, Hans-Peter Fiedler

      Pages 35-55

   2. Resistance to β-Lactams, a Self-Regenerating Problem

      • Jozsef Aszodi, André Bryskier

      Pages 57-83

   3. Resistance to aminoglycoside Antibiotics: Function meets structure

      • Gerard D. Wright, Albert M. Berghuis

      Pages 85-98

   4. The Genetics and Biochemistry of Resistance to Glycopeptide Antibiotics

      • P. E. Reynolds

      Pages 99-115

   5. β-Lactamases, an Old but Ever Renascent Problem

      • André Matagne, Moreno Galleni, Nezha Laraki, Gianfranco Amicosante, Gianmaria Rossolini, Jean-Marie Frère

      Pages 117-129

   6. Metabolic Flux Analysis in Streptomyces Coelicolor: Effect of nitrogen source

      • Fereshteh Naeimpoor, Ferda Mavituna

      Pages 131-145

   7. Metabolic Engineering of the Lysine Pathway for β-Lactam Overproduction in Penicillium Chrysogenum

      • Casqueiro J., Bañuelos O., Gutiérrez S., Martín J.F.

      Pages 147-159

   8. Glycosylation of Antibiotics and Other Agents from Actinomycetes

      • Wolfgang Piepersberg

      Pages 161-168

   9. Enzymatic Synthesis of Amoxicillin

      • A.C. Spiess, V. Kasche

      Pages 169-192

4. Production of Therapeutic Antibodies

   1. New Recombinant Bi- and Trispecific Antibody Derivatives

      • Nico Mertens, Reinilde Schoonjans, An Willems, Steve Schoonooghe, Jannick Leoen, Johan Grooten

      Pages 195-208

   2. Advantages of Single-Domain Antigen-Binding Fragments Derived from Functional Camel Heavy-Chain Antibodied

      • Muyldermans Serge, Conrath Katja, Vu Khoa Bang, Serrao Teresa, Busch Magnus, Backmann Natasha et al.

      Pages 209-216

5. Heterologous Protein Production: New Production Strategies

   1. Furin as a Tool for the Endoproteolytic Maturation of Susceptible Recombinant Biopharmaceuticals

      • M. Himmelspach, B. Plaimauer, F. Dorner, U. Schlokat

      Pages 219-248

   2. Development of Bioprocesses for the Generation of Anti-Inflammatory, Anti-Viral and Anti-Leukaemic Agents

      • Mahmoud Mahmoudian

      Pages 249-265

   3. Apoptosis and Bioprocess Technology

      • R.P. Singh, M. Al-Rubeai

      Pages 267-275

   4. Gram-Positive Bacteria as Host Cells for Heterologous Production of Biopharmaceuticals

      • Lieve Van Mellaert, Jozef Anné

      Pages 277-300

   5. Multiple Pathways of Exoprotein Secretion in Gram-Negative Bacteria

      • Anthony P Pugsley

      Pages 301-311

   6. Alteration of Metabolic Flux Distributions in Recombinant Escherichia Coli in Response to Heterologous Protein Production

      • Jan Weber, Ursula Rinas

      Pages 313-337

The present book entitled “Novel Frontiers in the Production of Compounds for Biomedical Uses” can perhaps be placed in its best perspective by the Shakespearean character in The Tempest who exclaimed" What’s past is prologue”. Indeed, this compilation of some of the outstanding presentations in the field of biomedicine made at th the 9 European Congress on Biotechnology (Brussels, Belgium, July 11-15, 1999) not only reflects the achievements of the recent past, but provides a privileged glimpse of the biotechnology that is emerging in the first decade of the new Millennium. It is becoming increasingly apparent that biotechnology is offering biomedicine novel approaches and solutions to develop a sorely needed new generation of biopharmaceuticals. This is all the more necessary because in recent years, new diseases have emerged with extraordinary lethality in all corners of the globe, while age-related chronic illnesses have filled the gap wherever biomedicine has made successful inroads. The rise of antibiotic resistance also poses major threats to public health. Thus, as disease patterns evolve, the rational development of new drugs is becoming urgent, not only for the clinical outcome of patients, but also in optimising the allocation of scarce health care resources through the use of cost-effective productions methods. It is in response to all these challenges that biotechnology offers new strategies that go beyond the more traditional approaches. By the mid-1990’s, the number of recombinant products approved annually for therapeutic use reached double digits. With the advent of the genomics revolution.

• Biomaterial
• Biomedical application
• DNA
• biochemistry
• biotechnology
• cells
• proteins

• Innogenetics N.V., Ghent, Belgium

  Annie Broekhoven, Fred Shapiro

• Catholic University of Leuven, Leuven, Belgium

  Jozef Anné

Policies and ethics